Cargando…
Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1
Only palliative therapeutic options exist for the treatment of Alzheimer’s Disease; no new successful drug candidates have been developed in over 15 years. The widely used clinical anticoagulant heparin has been reported to exert beneficial effects through multiple pathophysiological pathways involv...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067017/ https://www.ncbi.nlm.nih.gov/pubmed/33916819 http://dx.doi.org/10.3390/md19040203 |
_version_ | 1783682703361572864 |
---|---|
author | Mycroft-West, Courtney J. Devlin, Anthony J. Cooper, Lynsay C. Guimond, Scott E. Procter, Patricia Guerrini, Marco Miller, Gavin J. Fernig, David G. Yates, Edwin A. Lima, Marcelo A. Skidmore, Mark A. |
author_facet | Mycroft-West, Courtney J. Devlin, Anthony J. Cooper, Lynsay C. Guimond, Scott E. Procter, Patricia Guerrini, Marco Miller, Gavin J. Fernig, David G. Yates, Edwin A. Lima, Marcelo A. Skidmore, Mark A. |
author_sort | Mycroft-West, Courtney J. |
collection | PubMed |
description | Only palliative therapeutic options exist for the treatment of Alzheimer’s Disease; no new successful drug candidates have been developed in over 15 years. The widely used clinical anticoagulant heparin has been reported to exert beneficial effects through multiple pathophysiological pathways involved in the aetiology of Alzheimer’s Disease, for example, amyloid peptide production and clearance, tau phosphorylation, inflammation and oxidative stress. Despite the therapeutic potential of heparin as a multi-target drug for Alzheimer’s disease, the repurposing of pharmaceutical heparin is proscribed owing to the potent anticoagulant activity of this drug. Here, a heterogenous non-anticoagulant glycosaminoglycan extract, obtained from the shrimp Litopenaeus vannamei, was found to inhibit the key neuronal β-secretase, BACE1, displaying a more favorable therapeutic ratio compared to pharmaceutical heparin when anticoagulant activity is considered. |
format | Online Article Text |
id | pubmed-8067017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80670172021-04-25 Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1 Mycroft-West, Courtney J. Devlin, Anthony J. Cooper, Lynsay C. Guimond, Scott E. Procter, Patricia Guerrini, Marco Miller, Gavin J. Fernig, David G. Yates, Edwin A. Lima, Marcelo A. Skidmore, Mark A. Mar Drugs Article Only palliative therapeutic options exist for the treatment of Alzheimer’s Disease; no new successful drug candidates have been developed in over 15 years. The widely used clinical anticoagulant heparin has been reported to exert beneficial effects through multiple pathophysiological pathways involved in the aetiology of Alzheimer’s Disease, for example, amyloid peptide production and clearance, tau phosphorylation, inflammation and oxidative stress. Despite the therapeutic potential of heparin as a multi-target drug for Alzheimer’s disease, the repurposing of pharmaceutical heparin is proscribed owing to the potent anticoagulant activity of this drug. Here, a heterogenous non-anticoagulant glycosaminoglycan extract, obtained from the shrimp Litopenaeus vannamei, was found to inhibit the key neuronal β-secretase, BACE1, displaying a more favorable therapeutic ratio compared to pharmaceutical heparin when anticoagulant activity is considered. MDPI 2021-04-03 /pmc/articles/PMC8067017/ /pubmed/33916819 http://dx.doi.org/10.3390/md19040203 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mycroft-West, Courtney J. Devlin, Anthony J. Cooper, Lynsay C. Guimond, Scott E. Procter, Patricia Guerrini, Marco Miller, Gavin J. Fernig, David G. Yates, Edwin A. Lima, Marcelo A. Skidmore, Mark A. Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1 |
title | Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1 |
title_full | Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1 |
title_fullStr | Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1 |
title_full_unstemmed | Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1 |
title_short | Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer’s Disease β Secretase, BACE1 |
title_sort | glycosaminoglycans from litopenaeus vannamei inhibit the alzheimer’s disease β secretase, bace1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067017/ https://www.ncbi.nlm.nih.gov/pubmed/33916819 http://dx.doi.org/10.3390/md19040203 |
work_keys_str_mv | AT mycroftwestcourtneyj glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT devlinanthonyj glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT cooperlynsayc glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT guimondscotte glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT procterpatricia glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT guerrinimarco glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT millergavinj glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT fernigdavidg glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT yatesedwina glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT limamarceloa glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 AT skidmoremarka glycosaminoglycansfromlitopenaeusvannameiinhibitthealzheimersdiseasebsecretasebace1 |